Literature DB >> 33495638

Transient blood thinning during extracorporeal blood purification via the inactivation of coagulation factors by hydrogel microspheres.

Xin Song1, Haifeng Ji1, Yupei Li2,3, Yuqin Xiong2, Li Qiu4, Rui Zhong5, Meng Tian6, Jayachandran N Kizhakkedathu7, Baihai Su2,3, Qiang Wei1,8,9, Weifeng Zhao10, Changsheng Zhao11.   

Abstract

During extracorporeal blood purification, anticoagulants are administered to prevent thrombogenesis. However, haemorrhagic complications owing to near-complete inactivation of blood coagulation and delayed recovery of haemostasis pose serious risks to patients. Here, we show in vitro and in beagle dogs that hydrogel microspheres that adsorb the coagulation factors VIII, IX and XI provide transient blood thinning when placed in the extracorporeal circuit before blood purification. The microspheres inhibited the activities of the coagulation factors by levels (~8-30%) similar to those occurring in mild haemophilia. On its reintroduction into the animal, the purified pseudo-haemophilic blood favoured faster recovery of haemostasis. The transient blood-thinning strategy may increase the safety of clinical blood-purification procedures.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33495638     DOI: 10.1038/s41551-020-00673-x

Source DB:  PubMed          Journal:  Nat Biomed Eng        ISSN: 2157-846X            Impact factor:   25.671


  40 in total

1.  Use of hemodialysis and hemoperfusion in poisoned patients.

Authors:  William J Holubek; Robert S Hoffman; David S Goldfarb; Lewis S Nelson
Journal:  Kidney Int       Date:  2008-09-17       Impact factor: 10.612

Review 2.  The systemic nature of CKD.

Authors:  Carmine Zoccali; Raymond Vanholder; Ziad A Massy; Alberto Ortiz; Pantelis Sarafidis; Friedo W Dekker; Danilo Fliser; Denis Fouque; Gunnar H Heine; Kitty J Jager; Mehmet Kanbay; Francesca Mallamaci; Gianfranco Parati; Patrick Rossignol; Andrzej Wiecek; Gerard London
Journal:  Nat Rev Nephrol       Date:  2017-04-24       Impact factor: 28.314

Review 3.  What are the anticoagulation options for intermittent hemodialysis?

Authors:  Andrew Davenport
Journal:  Nat Rev Nephrol       Date:  2011-07-05       Impact factor: 28.314

4.  Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease.

Authors:  Justin Cheung; Andrea Yu; Joseph LaBossiere; Qiaohao Zhu; Richard N Fedorak
Journal:  Gastrointest Endosc       Date:  2010-01       Impact factor: 9.427

5.  Heparin free dialysis: comparative data and results in high risk patients.

Authors:  R J Caruana; R M Raja; J V Bush; M S Kramer; S J Goldstein
Journal:  Kidney Int       Date:  1987-06       Impact factor: 10.612

Review 6.  Triggers, targets and treatments for thrombosis.

Authors:  Nigel Mackman
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

Review 7.  Artificial and bioartificial liver devices: present and future.

Authors:  B Carpentier; A Gautier; C Legallais
Journal:  Gut       Date:  2009-12       Impact factor: 23.059

8.  End-stage renal disease is associated with worse outcomes in hospitalized patients with peptic ulcer bleeding.

Authors:  Sravanthi Parasa; Udayakumar Navaneethan; Arun Raghav Mahankali Sridhar; Preethi G K Venkatesh; Kevin Olden
Journal:  Gastrointest Endosc       Date:  2013-01-26       Impact factor: 9.427

9.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.

Authors:  M Levine; M Gent; J Hirsh; J Leclerc; D Anderson; J Weitz; J Ginsberg; A G Turpie; C Demers; M Kovacs
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

Review 10.  Evolving importance of kidney disease: from subspecialty to global health burden.

Authors:  Kai-Uwe Eckardt; Josef Coresh; Olivier Devuyst; Richard J Johnson; Anna Köttgen; Andrew S Levey; Adeera Levin
Journal:  Lancet       Date:  2013-05-31       Impact factor: 79.321

View more
  2 in total

1.  A breakthrough trial of an artificial liver without systemic heparinization in hyperbilirubinemia beagle models.

Authors:  Yilin Wang; Shanshan Wang; Xueqin He; Yupei Li; Tao Xu; Lin Xu; Bo Yang; Xinnian Fan; Weifeng Zhao; Changsheng Zhao
Journal:  Bioact Mater       Date:  2022-07-06

2.  Wireless charging-mediated angiogenesis and nerve repair by adaptable microporous hydrogels from conductive building blocks.

Authors:  Ru-Siou Hsu; Ssu-Ju Li; Jen-Hung Fang; I-Chi Lee; Li-An Chu; Yu-Chun Lo; Yu-Jen Lu; You-Yin Chen; Shang-Hsiu Hu
Journal:  Nat Commun       Date:  2022-09-02       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.